Adaptation to 5-fluorouracil of the heterogeneous human colon tumor cell line HT-29 results in the selection of cells committed to differentiation.
The HT-29 cell line contains a small proportion of differentiated polarized, enterocytic and mucus-secreting cell types (less than 95%) which can be selected under various pressure conditions, e.g., glucose deprivation or methotrexate. The purpose of the present work was to investigate whether this also applies to 5-fluorouracil (FUra). Stepwise adaptation of exponentially growing cells to 1, 5, 10 and 20 microM FUra results, after a phase of high mortality, in the emergence of adapted sub-populations with stable growth rates and curves, and IC50 6, 18, 37, and 110 times higher than in untreated cells respectively. FUra-adapted cells are all differentiated, according to 2 phenotypes: (I) polarized dome-forming cells which express carcinoembryonic antigen at their apical surface and (2) goblet cells which secrete a mucus of colonic immunoreactivity. These phenotypes are present in the parental population and are different from those selected e.g., by glucose deprivation or methotrexate. This differentiation pattern is maintained when the cells are subcultured in drug-free medium. Resistance to FUra is acquired through gene amplification as substantiated by a 4- to 6-fold increase of thymidylate synthase gene copies in cells stably adapted to the drug. Whether the same mechanism or others are responsible for the first steps of resistance to FUra remains to be elucidated. Altogether, these results support the hypothesis that some of the cells which are present in the parental line and are committed to differentiation possess advantages which allow them to immediately resist and secondarily adapt to FUra. Comparison of the differentiation characteristics of FUra-adapted cells with those from cells selected under other pressure conditions suggests that resistance and adaptation to either type of pressure may depend on the differentiated phenotype to which the cells are committed.
Unité de Recherches sur la Différenciation Cellulaire Intestinale, INSERM U178, Villejuif, France.
T
T
Lesuffleur
A
A
Kornowski
C
C
Luccioni
M
M
Muleris
A
A
Barbat
J
J
Beaumatin
E
E
Dussaulx
B
B
Dutrillaux
A
A
Zweibaum
D015152:Blotting, Northern; D015139:Blotting, Southern; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000235:genetics / Q000473:pathology*; D004351:Drug Resistance; D005455:Fluorescent Antibody Technique; D005472:Fluorouracil / Q000494:pharmacology*; D005784:Gene Amplification; D006801:Humans; D007621:Karyotyping; D008854:Microscopy, Electron; D012333:RNA, Messenger / Q000378:metabolism; D013940:Thymidylate Synthase / Q000235:genetics; D014407:Tumor Cells, Cultured
D012333:RNA, Messenger; D013940:Thymidylate Synthase; D005472:Fluorouracil